Arbutus Biopharma Corp (ABUS) stock
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 12/3081% below fair value
$4.09+0.06 (+1.49%)
Close on Nov 13, 2026Market cap $809.20MP/E 3.7Yield –
Arbutus Biopharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Arbutus Biopharma's operating income for the twelve months ending Sep 30, 2026 was $147.16M. For fiscal 2025 it was -$38.16M. The highest annual figure on record is -$10.69M in fiscal 2011.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$38.16M | – |
| FY2024 | Dec 31, 2024 | -$76.32M | – |
| FY2023 | Dec 31, 2023 | -$78.10M | – |
| FY2022 | Dec 31, 2022 | -$65.46M | – |
| FY2021 | Dec 31, 2021 | -$73.52M | – |
| FY2020 | Dec 31, 2020 | -$57.81M | – |
| FY2019 | Dec 31, 2019 | -$143.90M | – |
| FY2018 | Dec 31, 2018 | -$89.78M | – |
| FY2017 | Dec 31, 2017 | -$110.93M | – |
| FY2016 | Dec 31, 2016 | -$491.64M | – |
| FY2015 | Dec 31, 2015 | -$103.92M | – |
| FY2014 | Dec 31, 2014 | -$33.43M | – |
| FY2013 | Dec 31, 2013 | -$12.15M | – |
| FY2012 | Dec 31, 2012 | -$12.95M | – |
| FY2011 | Dec 31, 2011 | -$10.69M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$10.49M | – |
| Q2 FY2026 | Jun 30, 2026 | -$5.96M | -500.8% |
| Q1 FY2026 | Mar 31, 2026 | $168.91M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.29M | – |
| Q3 FY2025 | Sep 30, 2025 | -$8.66M | – |
| Q2 FY2025 | Jun 30, 2025 | $1.49M | – |
| Q1 FY2025 | Mar 31, 2025 | -$25.70M | – |
| Q4 FY2024 | Dec 31, 2024 | -$13.93M | – |
| Q3 FY2024 | Sep 30, 2024 | -$21.44M | – |
| Q2 FY2024 | Jun 30, 2024 | -$21.58M | – |
| Q1 FY2024 | Mar 31, 2024 | -$19.36M | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.75M | – |
| Q3 FY2023 | Sep 30, 2023 | -$21.56M | – |
| Q2 FY2023 | Jun 30, 2023 | -$18.39M | – |
| Q1 FY2023 | Mar 31, 2023 | -$17.41M | – |
| Q4 FY2022 | Dec 31, 2022 | -$22.56M | – |
| Q3 FY2022 | Sep 30, 2022 | -$17.81M | – |
| Q2 FY2022 | Jun 30, 2022 | -$14.11M | – |
| Q1 FY2022 | Mar 31, 2022 | -$10.97M | – |
| Q4 FY2021 | Dec 31, 2021 | -$20.80M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.41M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.64M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.68M | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.30M | – |
| Q3 FY2020 | Sep 30, 2020 | -$15.22M | – |
| Q2 FY2020 | Jun 30, 2020 | -$13.14M | – |
| Q1 FY2020 | Mar 31, 2020 | -$13.15M | – |
| Q4 FY2019 | Dec 31, 2019 | -$13.09M | – |
| Q3 FY2019 | Sep 30, 2019 | -$91.03M | – |
| Q2 FY2019 | Jun 30, 2019 | -$20.65M | – |
| Q1 FY2019 | Mar 31, 2019 | -$19.20M | – |
| Q4 FY2018 | Dec 31, 2018 | -$16.90M | – |
| Q3 FY2018 | Sep 30, 2018 | -$32.43M | – |
| Q2 FY2018 | Jun 30, 2018 | -$22.05M | – |
| Q1 FY2018 | Mar 31, 2018 | -$18.41M | – |
| Q4 FY2017 | Dec 31, 2017 | -$60.25M | – |
| Q3 FY2017 | Sep 30, 2017 | -$12.90M | – |
| Q2 FY2017 | Jun 30, 2017 | -$19.49M | – |
| Q1 FY2017 | Mar 31, 2017 | -$18.30M | – |
| Q4 FY2016 | Dec 31, 2016 | -$257.44M | – |
See a number that looks wrong?